Tobias L. Freitag

Tobias L. Freitag

Auto-generated profile, based on publicly available information

Tobias L. Freitag

Translational Immunology Research Program, Faculty of Medicine University of Helsinki Helsinki Finland

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 December 2012 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
YJYvonne Junker
Yvonne Junker
SZSebastian Zeissig
Sebastian Zeissig
SKSeong-Jun Kim
Seong-Jun Kim
DBDonatella Barisani
Donatella Barisani
HWHerbert Wieser
Herbert Wieser
DSDetlef Schuppan
Detlef Schuppan
Ingestion of wheat, barley, or rye triggers small intestinal inflammation in patients with celiac disease. Specifically, the storage proteins of these cereals (gluten) elicit an adaptive Th1-mediated immune response in individuals carrying HLA-DQ2 or HLA-DQ8 as major genetic predisposition. This well-defined role of adaptive immunity contrasts with an ill-defined component of innate immunity in celiac disease. We identify the α-amylase/trypsin inhibitors (ATIs) CM3 and 0.19, pest resistance molecules in wheat, as strong activators of innate immune responses in monocytes, macrophages, and dendritic cells. ATIs engage the TLR4–MD2–CD14 complex and lead to up-regulation of maturation markers and elicit release of proinflammatory cytokines in cells from celiac and nonceliac patients and in celiac patients’ biopsies. Mice deficient in TLR4 or TLR4 signaling are protected from intestinal and systemic immune responses upon oral challenge with ATIs. These findings define cereal ATIs as novel contributors to celiac disease. Moreover, ATIs may fuel inflammation and immune reactions in other intestinal and nonintestinal immune disorders.

1 May 2020 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
TFTobias L. Freitag
Tobias L. Freitag
JPJoseph R. Podojil
Joseph R. Podojil
RPRyan Pearson
Ryan Pearson
FFFrank J. Fokta
Frank J. Fokta
CSCecilia Sahl
Cecilia Sahl
DGDaniel R. Getts
Daniel R. Getts

1 May 2011 in Gastroenterology
Verified
Journal Article
Closed access
YPYury V. Popov
Yury V. Popov
DSDeanna Y. Sverdlov
Deanna Y. Sverdlov
ASAnisha K. Sharma
Anisha K. Sharma
KBK. Ramakrishnan Bhaskar
K. Ramakrishnan Bhaskar
SLShaoyong Li
Shaoyong Li
DSDetlef Schuppan
Detlef Schuppan

15 December 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
OVOuti Vaarala
Outi Vaarala
AVArja Vuorela
Arja Vuorela
MPMarkku Partinen
Markku Partinen
MBMarc Henrik Baumann
Marc Henrik Baumann
TFTobias L Freitag
Tobias L Freitag
TKTerhi Kilpi
Terhi Kilpi
Narcolepsy results from immune-mediated destruction of hypocretin secreting neurons in hypothalamus, however the triggers and disease mechanisms are poorly understood. Vaccine-attributable risk of narcolepsy reported so far with the AS03 adjuvanted H1N1 vaccination Pandemrix has been manifold compared to the AS03 adjuvanted Arepanrix, which contained differently produced H1N1 viral antigen preparation. Hence, antigenic differences and antibody response to these vaccines were investigated. Increased circulating IgG-antibody levels to Pandemrix H1N1 antigen were found in 47 children with Pandemrix-associated narcolepsy when compared to 57 healthy children vaccinated with Pandemrix. H1N1 antigen of Arepanrix inhibited poorly these antibodies indicating antigenic difference between Arepanrix and Pandemrix. High-resolution gel electrophoresis quantitation and mass spectrometry identification analyses revealed higher amounts of structurally altered viral nucleoprotein (NP) in Pandemrix. Increased antibody levels to hemagglutinin (HA) and NP, particularly to detergent treated NP, was seen in narcolepsy. Higher levels of antibodies to NP were found in children with DQB1*06∶02 risk allele and in DQB1*06∶02 transgenic mice immunized with Pandemrix when compared to controls. This work identified 1) higher amounts of structurally altered viral NP in Pandemrix than in Arepanrix, 2) detergent-induced antigenic changes of viral NP, that are recognized by antibodies from children with narcolepsy, and 3) increased antibody response to NP in association of DQB1*06∶02 risk allele of narcolepsy. These findings provide a link between Pandemrix and narcolepsy. Although detailed mechanisms of Pandemrix in narcolepsy remain elusive, our results move the focus from adjuvant(s) onto the H1N1 viral proteins.

21 November 2019 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
TFTobias L. Freitag
Tobias L. Freitag
AHAnna Hartikainen
Anna Hartikainen
HJHanne Jouhten
Hanne Jouhten
CSCecilia Sahl
Cecilia Sahl
SMSeppo Meri
Seppo Meri
Reetta SatokariReetta Satokari
Reetta Satokari
Fecal microbiota transplantation (FMT) is an effective therapy for recurrent Clostridioides difficile infection (rCDI) and is also considered a potential treatment for a wide range of intestinal and systemic diseases. FMT corrects the microbial dysbiosis associated with rCDI, and the engraftment of donor microbiota is likely to play a key role in treatment efficacy. For disease indications other than rCDI, FMT treatment efficacy has been moderate. This may be partly due to stronger resilience of resident host microbiota in patients who do not suffer from rCDI. In rCDI, patients typically have undergone several antibiotic treatments prior to FMT, depleting the microbiota. In this study, we addressed the effect of broad-spectrum antibiotics (Ab) as a pre-treatment to FMT on the engraftment of donor microbiota in recipients. We conducted a pre-clinical study of FMT between two healthy mouse strains, Balb/c as donors and C57BL/6 as recipients, to perform FMT within the same species and to mimic interindividual FMT between human donors and patients. Microbiota composition was assessed with high-throughput 16S rDNA amplicon sequencing. The microbiota of Balb/c and C57BL/6 mice differed significantly, which allowed for the assessment of microbiota transplantation from the donor strain to the recipient. Our results showed that Ab-treatment depleted microbiota in C57BL/6 recipient mice prior to FMT. The diversity of microbiota did not recover spontaneously to baseline levels during 8 weeks after Ab-treatment, but was restored already at 2 weeks in mice receiving FMT. Interestingly, pre-treatment with antibiotics prior to FMT did not increase the overall similarity of the recipient’s microbiota to that of the donor’s, as compared with mice receiving FMT without Ab-treatment. Pre-treatment with Ab improved the establishment of only a few donor-derived taxa, such as Bifidobacterium, in the recipients, thus having a minor effect on the engraftment of donor microbiota in FMT. In conclusion, pre-treatment with broad-spectrum antibiotics did not improve the overall engraftment of donor microbiota, but did improve the engraftment of specific taxa. These results may inform future therapeutic studies of FMT.